Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Foreign pharmaceutical companies continue to increase their investments in Shanghai, with AstraZeneca expanding its entire cell therapy chain.
Shanghai’s biopharmaceutical industry continues to attract global capital investment, with foreign medical companies increasing their investments in Shanghai. AstraZeneca announced today that it plans to establish a commercial production and supply base for cell therapy and an innovation center in Shanghai, becoming the first global biopharmaceutical company in China with end-to-end cell therapy capabilities. On the same day, the company signed a multi-party cooperation memorandum of understanding with the Shanghai Municipal Science and Technology Commission and leading UK research and financial institutions. (Xinmin Evening News)